Climb Bio, Inc. has made a significant update regarding its beneficial ownership in a recent SEC filing. The company reported changes in the number of shares of common stock deemed beneficially owned by its reporting persons, reflecting an increase in the outstanding shares. This move is essential for maintaining transparency and compliance in the pharmaceutical preparations sector.
Founded as a pharmaceutical preparation company, Climb Bio, Inc. trades on the Nasdaq under the ticker symbol CLYM. The company has undergone several filings recently, including a Schedule 13D/A on November 9, 2026, and a quarterly report on November 5, 2026. These filings help to provide a clearer picture of the company’s financial standing and ownership structure.
The Schedule 13D/A filing indicates that RA Capital Management, L.P. and its affiliates collectively hold a significant stake in Climb Bio. According to the filing, RA Capital and its related entities own approximately 33% of Climb Bio's common stock. This includes shares held directly by various funds managed by RA Capital, such as the RA Capital Healthcare Fund and the RA Capital Nexus Fund III.
"This Amendment No. 11 is being filed to report the change in the number of shares of common stock deemed beneficially owned by the Reporting Persons by virtue of the increase in the Issuer's outstanding common stock and not as a result of any acquisition or disposition of securities by the Reporting Persons," the filing states.
The filing highlights that the increase in shares is not due to any new acquisitions but rather a result of the company's actions. This information is crucial for investors and analysts monitoring Climb Bio's performance and ownership dynamics. The company’s transparency in reporting ownership changes reflects its commitment to regulatory compliance and investor relations.
RA Capital Management, a significant player in the investment management space, has been active in the pharmaceutical sector, and its substantial ownership stake in Climb Bio could influence the company's strategic decisions moving forward. The filing also notes that the reporting persons have delegated voting and investment powers over the reported securities, which adds another layer of complexity to the ownership structure.
As the pharmaceutical preparations industry continues to evolve, the implications of this filing may extend beyond Climb Bio itself. Investors in similar sectors may reassess their strategies in light of ownership changes and the potential for increased stock volatility. The filing serves as a reminder of the importance of monitoring beneficial ownership, especially in a rapidly changing market.
Looking ahead, the filing does not specify what actions may follow this update. However, it sets the stage for ongoing scrutiny of Climb Bio's stock performance and corporate governance practices. Investors and analysts will likely keep a close eye on future filings and any developments that may arise from this significant ownership disclosure.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





